Evidence map›Paper›PMID 41206040›Full record

ArticleNucleic acids research2025

Modulating NLRP3 splicing with antisense oligonucleotides to control pathological inflammation.

Roni Klein, Janset Onyuru, Jessica L Centa, Estela M Viera, Christopher D Putnam, Hal M Hoffman, Michelle L Hastings

Abstract read
In one paragraph

Article in Nucleic acids research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors.

Roni KleinCenter for Genetic Diseases, Chicago Medical School, Rosalind Franklin University of Medicine and Science, North Chicago, IL 60064, United States.ORCID 0000-0001-8998-4461
Janset OnyuruDepartment of Pediatrics, University of California San Diego, La Jolla, CA 92093, United States.
Jessica L CentaCenter for Genetic Diseases, Chicago Medical School, Rosalind Franklin University of Medicine and Science, North Chicago, IL 60064, United States.
Estela M VieraCenter for Genetic Diseases, Chicago Medical School, Rosalind Franklin University of Medicine and Science, North Chicago, IL 60064, United States.
Christopher D PutnamDepartment of Medicine, University of California San Diego, La Jolla, CA 92093, United States.
Hal M HoffmanDepartment of Pediatrics, University of California San Diego, La Jolla, CA 92093, United States.
Michelle L HastingsCenter for Genetic Diseases, Chicago Medical School, Rosalind Franklin University of Medicine and Science, North Chicago, IL 60064, United States.ORCID 0000-0002-4253-9261

Funding

U of Calif, San Diego Neuroscience Microscopy ImagingP30NS047101 · NINDS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI GLEESON, JOSEPH G, ZHENG, BINHAI · 2003 to 2022
$9.0M
Prevention of complement and immune-mediated Lewy body dementiaR01AG060195 · NIA · MCLEAN HOSPITAL · PI HALLETT, PENELOPE JANE, HASTINGS, MICHELLE L · 2018 to 2022
$2.9M
NIH HHS P30 NS047101NIH HHS R01 AG060195NIH HHS R01 AI15586901University of Michigan
6 · The paper itself

Abstract

Inflammation has an essential role in healing. However, over-active inflammation disrupts normal cellular functions and can be life-threatening when not resolved. The NLR family pyrin domain-containing 3 (NLRP3) inflammasome, a component of the innate immune system, is an intracellular multiprotein complex that senses stress-associated signals, and, for this reason is a promising therapeutic target for treating unresolved, pathogenic inflammation. Alternative splicing of NLRP3 RNA has been suggested as a regulatory mechanism for inflammasome activation, as some spliced isoforms encode NLRP3 proteins with compromised function. Here, we take advantage of this natural regulatory mechanism and devise a way to control pathogenic inflammation using splice-switching antisense oligonucleotides (ASOs). To identify and induce NLRP3 isoforms lacking inflammatory activity, we tested a series of ASOs, each targeting a different exon, to determine the most effective strategy for downregulating NLRP3. We identify several ASOs that modulate NLRP3 splicing, reduce NLRP3 protein, and decrease inflammasome signaling in vitro. The most effective ASO suppresses systemic inflammation in vivo in mouse models of acute inflammation and cryopyrin-associated periodic syndrome. Overall, these results demonstrate how ASOs can be used to systematically engineer proteins with modified functions and treat pathological inflammation in mice by reducing functional NLRP3.

Indexed as

Alternative SplicingInflammationNLR Family, Pyrin Domain-Containing 3 ProteinOligonucleotides, AntisenseAnimalsDisease Models, AnimalExonsHumansInflammasomesMiceMice, Inbred C57BLProtein IsoformsSignal TransductionInflammasomesNLR Family, Pyrin Domain-Containing 3 ProteinNlrp3 protein, mouseOligonucleotides, AntisenseProtein Isoforms

Identifiers

PMID41206040
PMCPMC12596483

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.